Amphastar Pharmaceuticals (AMPH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.91
- Estimate
- $0.61
- Surprise
- +48.3%
- Revenue (period 2026-06-30)
- $183.9M
- Score at report (before → after)
- 5.9 → 5.9/10
Revenue source: xbrl.
How the report landed
Amphastar Pharmaceuticals (AMPH) beat the $0.61 estimate with diluted EPS of $0.91 — a large 48.3% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.9/10) to Sell at 5.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AMPH Sell at 5.5/10.
2 of the last 4 quarters beat the estimate; this quarter's +48.3% surprise compares with a -0.0% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Supplier: third-party BAQSIMI manufacturer
- Analyst target reached - limited upside remaining
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $23.95
- Price target
- $27.54
- Stop
- $22.53
- Upside to target
- +15.0%
The stock trades at 14.2× trailing but 7.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 71 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
AMPH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.01B
- P/E (fwd)
- 7.4
- P/E (ttm)
- 14.2
- 52-week range
- $16.65–$29.52
- Off 52-week high
- 18.9%
- RSI (14)
- 71
- Volume vs avg
- 1.26×
- Score today
- 5.5/10